Weight
Retatrutide
Metabolic
40
Amino acids
Molecular weight
Peptide
Type
Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medications.
Top researched benefits
Overview of Retatrutide
Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation.
Weight Loss
- Clinical trials show 17.5% weight loss at 24 weeks and 24.2% at 48 weeks.
- Continuous weight loss with no plateau at 48 weeks suggests greater long-term potential.
- Addresses obesity through appetite suppression, energy expenditure, and metabolic efficiency.
Type 2 Diabetes
- HbA1c reductions up to 2.16% with 82% achieving target levels below 6.5%.
- Balanced glycemic control with minimal hypoglycemia risk.
- Marked improvements in sensitivity with potential for reduced exogenous insulin requirements.
Cardiovascularmetabolic
- Non-HDL cholesterol reductions up to 26.9%, triglyceride reductions up to 40.6%.
- Consistent decreases in systolic and diastolic blood pressure across trials.
- Up to 82% reduction in liver fat with normalization in 90% of participants.
Storage
Reconstituted: 2-8°C, use within 28 days
Frequency
Once weekly (same day each week)
Typical Dose
0.5mg starting, titrate up to 8-12mg weekly
Cycle Duration
Continuous therapy as prescribed
Chemical Makeup
Key benefits
Superior weight loss (24.2% at 48 weeks)
Improved glycemic control (HbA1c reduction up to 2.16%)
Enhanced cardiovascular benefits
Hepatic fat reduction (up to 82%)
Triple mechanism addresses obesity through multiple pathways
Community interest
This peptide is still gaining traction in the community.
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesRetatrutide Molecular Information
View the scientifc details of Retatrutide.
40
Amino Acids
Retatrutide
His
His
Position 1
Sec
Sec
Position 2
Glu
Glu
Position 3
Gly
Gly
Position 4
Thr
Thr
Position 5
Phe
Phe
Position 6
Thr
Thr
Position 7
Ser
Ser
Position 8
Asp
Asp
Position 9
Val
Val
Position 10
Ser
Ser
Position 11
Ser
Ser
Position 12
Tyr
Tyr
Position 13
Leu
Leu
Position 14
Glu
Glu
Position 15
Gly
Gly
Position 16
Gln
Gln
Position 17
Ala
Ala
Position 18
Ala
Ala
Position 19
Lys
Lys
Position 20
Glu
Glu
Position 21
Phe
Phe
Position 22
Ile
Ile
Position 23
Ala
Ala
Position 24
Trp
Trp
Position 25
Leu
Leu
Position 26
Val
Val
Position 27
Arg
Arg
Position 28
Gly
Gly
Position 29
Arg
Arg
Position 30
Gly
Gly
Position 31
Pro
Pro
Position 32
Ser
Ser
Position 33
Ser
Ser
Position 34
Gly
Gly
Position 35
Ala
Ala
Position 36
Pro
Pro
Position 37
Pro
Pro
Position 38
Pro
Pro
Position 39
Ser
Ser
Position 40
Molecular Weight
4DaChain Length
40Amino AcidsType
PeptideRetatrutide Protocols
Weekly subcutaneous injection into abdomen, thigh, or upper arm with site rotation.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Starting Dose (Week 1-4) | 0.5 | 1 week range | SubQ |
| Low Maintenance (Week 4-8) | 1 | 1 week range | SubQ |
| Escalation (Week 8-12) | 2 | 1 week range | SubQ |
| Moderate (Week 12-16) | 4 | 1 week range | SubQ |
| Advanced (Week 16-20) | 8 | 1 week range | SubQ |
| Maximum Efficacy (Week 20+) | 12 | 1 week range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Allow vial to reach room temperature (15-20 minutes)
- Clean vial top with alcohol swab and air dry completely
- Add calculated bacteriostatic water slowly down vial side
- Gently swirl in circular motions—avoid vigorous shaking
- Allow full dissolution (2-3 minutes); solution should be clear and colorless
- Store reconstituted solution refrigerated at 2-8°C for up to 28 days
- Inject subcutaneously; rotate sites weekly
Retatrutide Cycle
The Retatrutide Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- Initial appetite suppression and mild GI effects as body adapts to triple hormone activation
- Week 2-4
- Noticeable food cravings reduction and portion size decrease; early weight loss (2-5%)
- Week 4-8
- Significant appetite control and steady weight loss (5-10%); improved glucose control
- Week 8-16
- Substantial weight reduction (10-18%) with enhanced energy expenditure
- Week 16-24
- Major weight loss milestone (15-22%) with cardiovascular benefits and liver fat reduction
- Week 24-48
- Maximum clinical efficacy (20-24.2%) with comprehensive metabolic improvements
Dosing tools
Retatrutide Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Injection Results
Based on your vial and dilution inputs.
Safe concentration range
Retatrutide
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Retatrutide vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Reference Guide
Dosing Cycle
- Peptide
- Retatrutide
- Dosing
- 0.5mg starting, titrate up to 8-12mg weekly
- Dosing Frequency
- Once weekly (same day each week)
- Cycle Duration
- Continuous therapy as prescribed
- Storage
- Reconstituted: 2-8°C, use within 28 days
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Retatrutide interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
Safe combination; BPC-157 may provide GI protective benefits during retatrutide use.
Weight
cag
Metabolic
Cagrilintide
MONITOR
Both cause significant GI effects. Not recommended without specialist supervision.
Weight
sem
Metabolic
Semaglutide
AVOID
Do not combine—overlapping GLP-1 agonist mechanisms increase severe hypoglycemia risk.
Weight
tir
Metabolic
Tirzepatide
AVOID
Do not combine with other dual/triple agonists—risk of severe hypoglycemia and excessive GI effects.
Side effects
Avoid: Do not take Retatrutide with Semaglutide, Tirzepatide.
Monitor: Be careful when combining Retatrutide with Cagrilintide.
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Stop signs
Severe persistent nausea or vomiting preventing adequate nutrition
Signs of pancreatitis: severe abdominal pain radiating to back
Severe hypoglycemia symptoms: confusion, dizziness, sweating
Excessive weight loss (>3 lbs per week consistently or >25% total body weight)
Gallbladder problems: severe right upper abdominal pain
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
RetatrutideResearch References
Retatrutide is an extensively studied compound
Retatrutide
Retatrutide is an extensively studied compound
Phase II Obesity Trial
Landmark RCT in 338 participants showing dose-dependent weight loss; 12mg dose achieved 24.2% reduction—highest recorded for any obesity medication. NEJM.
2023
Phase II Type 2 Diabetes Study
Trial in 281 participants with type 2 diabetes: 16.9% weight loss and HbA1c reductions up to 2.16%. The Lancet.
2023
MASLD Substudy
Metabolic dysfunction-associated steatotic liver disease study: 82% liver fat reduction with normalization in >90% at highest doses. Nature Medicine.
2024
Structural Insights into Triple Agonism
Cryo-EM structures reveal simultaneous activation of GLP-1R, GIPR, and GCGR, explaining superior clinical efficacy. Cell Discovery.
2024